Adaptive Biotechnologies Corporation (ADPT)

NMS – Real Time Price. Currency in USD

13.63

+0.09 (0.66%)

At close: May 12, 2026, 4:00 PM EDT

13.90

+0.27 (1.98%)

After-hours: May 12, 2026, 7:42 PM EDT

Stock details

Previous close: 13.81$
Day's range: 13.56 - 14.46$
52-week range: 8.5 - 20.76$
Volume: 1 522 091
Average volume: 1 951 509
Beta: 1.24
EPS (TTM): -0.32
PE ratio (TTM): N/A
Forward P/E: N/A
Market cap: 2 210 212 932
Shares outstanding: 160 044 383
Dividend yield: N/A
Next earnings date: 2026-08-05
Sector: Healthcare
Industry: Biotechnology

About the company

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and moni... read more

CEO: Chad Robins
Country: United States
IPO Date: 2019-06-27
Employees: 624
Fiscal Year End: January - December
Website: https://www.adaptivebiotech...

Revenue Breakdown

Minimal Residual Disease - Service / 69.62%

Immune Medicine - Collaboration / 14.90%

Immune Medicine - Service and Licensing / 8.43%

News

No Data

There are no news for this stock.

Chart: ADPT

Loading Chart...

Overall Score

3.4 / 1034%

Financial Strength

6.4

Profitability

2.8

Effectiveness

Growth

7.2

Forecast

5.4

Valuation

2.8

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	3.35	6.05	10
Quick ratio	3.22	5.63	10
Debt to Equity	0.96	0.30	6.0
Debt to Assets	0.41	1.04	5.0
Interest coverage	-6.31	-16.91	1.0
Weighted average score			6.4

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	185M	170M	179M	277M	295M
Gross Profit	106M	72M	97M	194M	212M
Operating Income	-198M	-202M	-153M	-57M	-46M
Net Income	-200M	-225M	-159M	-59M	-50M
EBITDA	-170M	-179M	-134M	-39M	-29M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	70.56	-11.73	10
Operating margin %	-25.70	-24.60	1.0
Net margin %	-28.27	-172.20	1.0
EBITDA margin %	-20.29	-201.27	1.0
Cash flow margin %	-13.46	-156.39	1.0
Weighted average score			2.8

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	-13.82	-57.97	1.0
ROE	-36.85	-63.56	1.0
ROIC	-18.56	-42.57	1.0
ROCE	-2.37	-71.10	1.0
Weighted average score			1.0

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	11.69	19.85	8.0
Next quarter	-24.8	-289.58	1.0
Current year	3.02	-22.76	2.5
Next year	22.65	45.17	10
Weighted average score			5.4

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	-1.12	-47.52	-44.43	-828.18	1.0
Y/Y	35.14	32.89	35	65.26	10
3y average	17.26	26.46	27.75	35.97	9.8
5y average	25.74	8.21	11.07	15.63	8.0
Weighted average score					7.2

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	N/A	-5.25	1.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	7.94	64.66	6.4
P/B	10.58	2.96	2.8
Weighted average score			2.8

DCF Model

DCF Model PeriodN/A

Discount rateN/A

Perpetual growth rateN/A

Revenue 5 year CAGRN/A

FCF 5 year CAGRN/A

Fair valueN/A

Stock price13.81$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$1

UndervaluedStock priceOvervalued

$13.81

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Chad Robins

Country

United States

IPO Date

2019-06-27

Employees

624

Fiscal Year End

January - December

Website

https://www.adaptivebiotech...

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

3.35

6.05

Quick ratio

3.22

5.63

Debt to Equity

0.96

0.30

6.0

Debt to Assets

0.41

1.04

5.0

Interest coverage

-6.31

-16.91

1.0

Weighted average score

6.4

METRIC

2022

2023

2024

2025

TTM

Total Revenue

185M

170M

179M

277M

295M

Gross Profit

106M

72M

97M

194M

212M

Operating Income

-198M

-202M

-153M

-57M

-46M

Net Income

-200M

-225M

-159M

-59M

-50M

EBITDA

-170M

-179M

-134M

-39M

-29M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

70.56

-11.73

Operating margin %

-25.70

-24.60

1.0

Net margin %

-28.27

-172.20

1.0

EBITDA margin %

-20.29

-201.27

1.0

Cash flow margin %

-13.46

-156.39

1.0

Weighted average score

2.8

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

-13.82

-57.97

1.0

ROE

-36.85

-63.56

1.0

ROIC

-18.56

-42.57

1.0

ROCE

-2.37

-71.10

1.0

Weighted average score

1.0

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

11.69

19.85

8.0

Next quarter

-24.8

-289.58

1.0

Current year

3.02

-22.76

2.5

Next year

22.65

45.17

Weighted average score

5.4

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

-1.12

-47.52

-44.43

-828.18

1.0

Y/Y

35.14

32.89

65.26

3y average

17.26

26.46

27.75

35.97

9.8

5y average

25.74

8.21

11.07

15.63

8.0

Weighted average score

7.2

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

N/A

-5.25

1.0

PEG (5yr expected)

N/A

0.27

1.0

P/S

7.94

64.66

6.4

P/B

10.58

2.96

2.8

Weighted average score

2.8

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Adaptive Biotechnologies Corporation (ADPT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Adaptive Biotechnologies Corporation (ADPT)

Stock details

About the company

Revenue Breakdown

News

Chart: ADPT

Overall Score

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$1

$13.81

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: ADPT

Overall Score

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$1

$13.81

Economic Moat

Octagon View

Strength & Weakness